Background Premature ventricular contraction （PVC） is one of the most common kinds of arrhythmias for which the treatment falls into dilemma. Previous clinical application showed that the traditional Chinese Medicin...Background Premature ventricular contraction （PVC） is one of the most common kinds of arrhythmias for which the treatment falls into dilemma. Previous clinical application showed that the traditional Chinese Medicine Shensongyangxin （SSYX） capsule is efficacious for the treatment of PVCs. This randomized clinical trial aimed to further evaluate the efficacy and safety of SSYX capsule on treating PVC. Methods The subjects who had frequent PVCs with or without organic heart disease and normal cardiac function were enrolled in the study. The primary endpoint was the change of PVC numbers after eight-week medication with SSYX capsule. The secondary endpoints included change of clinical symptoms related to PVCs and the safety evaluation of SSYX capsule. Totally 188 PVC patients were randomly enrolled in the non-organic heart disease PVCs trial and orally took either $SYX capsules or analogues （three times per day, 4 capsules one time）. A total of 671 PVCs patients were randomly enrolled in the organic heart disease PVCs trial, and orally took either SSYX capsules （three times per day, 4 capsules one time） or mexiletine tablet （three times per day, 150 mg one time）. The PVCs were monitored and calculated with 24-hour Holter electrocardiogram. Routine blood, liver and kidney function were tested before and after medication with SSYX capsule. Results SSYX capsules significantly decreased the PVCs numbers and alleviated the related symptoms in patients with or without organic heart disease. In non-organic heart disease group, SSYX capsules and the placebos decreased the PVCs from 12561.34±9777.93 to 4806.87±6507.17, and 12 605.69±8736.34 to 10364.94±9903.41, respectively. The total effective rate was 74.2% and 28.9% in SSYX and placebo groups （P〈0.001）. In organic heart disease group, SSYX capsule and mexiletine decreased the PVCs from 8641.01±8923.57 to 3853.68±7096.42, 8621.61±8367.74 to 5648.29±8667.38, respectively, The total effective rate was 65.8% and 50.7% in SSYX and mexiletine groups （P〈0.001）. In addition, SSYX capsule significantly alleviated PVCs-related symptoms such as palpitations, chest tightness, insomnia fatigue, and night sweats. No adverse cardiac events were observed except some slight gastrointestinal side effects during the study. Conclusions Compared with placebo or mexiletine, SSYX capsules have significant therapeutic efficacy in reducing PVCs numbers and alleviate PVCs-related symptoms.展开更多
Sudden cardiac death （SCD）, caused mainly by ventricular tachycardia and ventricular fibrillation, still remains a big clinical challenge in chronic heart failure （CHF）. Owing mainly to their strong prognostic ef...Sudden cardiac death （SCD）, caused mainly by ventricular tachycardia and ventricular fibrillation, still remains a big clinical challenge in chronic heart failure （CHF）. Owing mainly to their strong prognostic efficiency and easy detection, heart rate variability （HRV） and heart rate turbulence （HRT） are widely used in recent years as the predictors for the risk of SCD.展开更多
目的：观察参松养心胶囊辅治失眠症的临床疗效。方法将72例失眠症患者随机分为治疗组和对照组，各36例。2组患者均给予心理治疗和行为干预，在此基础上治疗组加服参松养心胶囊每次4粒，每天3次，疗程4周；早期辅以艾司唑仑每晚1 mg，疗...目的：观察参松养心胶囊辅治失眠症的临床疗效。方法将72例失眠症患者随机分为治疗组和对照组，各36例。2组患者均给予心理治疗和行为干预，在此基础上治疗组加服参松养心胶囊每次4粒，每天3次，疗程4周；早期辅以艾司唑仑每晚1 mg，疗程1周。对照组加服艾司唑仑每晚1 mg，疗程4周。观察治疗前后匹兹堡睡眠质量指数量表（ PSQI）变化及临床疗效，并记录药物不良反应。结果2组治疗后PSQI总分均有改善，差异均有统计学意义（ P ＜0．05），且治疗组优于对照组（ P ＜0．05）。治疗前和治疗后差值比较，治疗组在睡眠质量、入睡时间、睡眠时间、睡眠效率、催眠药物，日间功能改善方面优于对照组，差异有统计学意义（ P ＜0．05），而睡眠障碍评分无显著差异（ P ＞0．05）。疗程结束后治疗组总有效率为8．7％，高于照组的6．8％（χ2=0．130， P ＜0．05）；治疗组不良反应发生率为5．％，对照组为3．2％，2组比较差异有统计学意义（χ2＝1．72， P ＜0．01）。结论参松养心胶囊辅治失眠症安全而有效。展开更多
文摘Background Premature ventricular contraction （PVC） is one of the most common kinds of arrhythmias for which the treatment falls into dilemma. Previous clinical application showed that the traditional Chinese Medicine Shensongyangxin （SSYX） capsule is efficacious for the treatment of PVCs. This randomized clinical trial aimed to further evaluate the efficacy and safety of SSYX capsule on treating PVC. Methods The subjects who had frequent PVCs with or without organic heart disease and normal cardiac function were enrolled in the study. The primary endpoint was the change of PVC numbers after eight-week medication with SSYX capsule. The secondary endpoints included change of clinical symptoms related to PVCs and the safety evaluation of SSYX capsule. Totally 188 PVC patients were randomly enrolled in the non-organic heart disease PVCs trial and orally took either $SYX capsules or analogues （three times per day, 4 capsules one time）. A total of 671 PVCs patients were randomly enrolled in the organic heart disease PVCs trial, and orally took either SSYX capsules （three times per day, 4 capsules one time） or mexiletine tablet （three times per day, 150 mg one time）. The PVCs were monitored and calculated with 24-hour Holter electrocardiogram. Routine blood, liver and kidney function were tested before and after medication with SSYX capsule. Results SSYX capsules significantly decreased the PVCs numbers and alleviated the related symptoms in patients with or without organic heart disease. In non-organic heart disease group, SSYX capsules and the placebos decreased the PVCs from 12561.34±9777.93 to 4806.87±6507.17, and 12 605.69±8736.34 to 10364.94±9903.41, respectively. The total effective rate was 74.2% and 28.9% in SSYX and placebo groups （P〈0.001）. In organic heart disease group, SSYX capsule and mexiletine decreased the PVCs from 8641.01±8923.57 to 3853.68±7096.42, 8621.61±8367.74 to 5648.29±8667.38, respectively, The total effective rate was 65.8% and 50.7% in SSYX and mexiletine groups （P〈0.001）. In addition, SSYX capsule significantly alleviated PVCs-related symptoms such as palpitations, chest tightness, insomnia fatigue, and night sweats. No adverse cardiac events were observed except some slight gastrointestinal side effects during the study. Conclusions Compared with placebo or mexiletine, SSYX capsules have significant therapeutic efficacy in reducing PVCs numbers and alleviate PVCs-related symptoms.
文摘Sudden cardiac death （SCD）, caused mainly by ventricular tachycardia and ventricular fibrillation, still remains a big clinical challenge in chronic heart failure （CHF）. Owing mainly to their strong prognostic efficiency and easy detection, heart rate variability （HRV） and heart rate turbulence （HRT） are widely used in recent years as the predictors for the risk of SCD.
文摘目的：观察参松养心胶囊辅治失眠症的临床疗效。方法将72例失眠症患者随机分为治疗组和对照组，各36例。2组患者均给予心理治疗和行为干预，在此基础上治疗组加服参松养心胶囊每次4粒，每天3次，疗程4周；早期辅以艾司唑仑每晚1 mg，疗程1周。对照组加服艾司唑仑每晚1 mg，疗程4周。观察治疗前后匹兹堡睡眠质量指数量表（ PSQI）变化及临床疗效，并记录药物不良反应。结果2组治疗后PSQI总分均有改善，差异均有统计学意义（ P ＜0．05），且治疗组优于对照组（ P ＜0．05）。治疗前和治疗后差值比较，治疗组在睡眠质量、入睡时间、睡眠时间、睡眠效率、催眠药物，日间功能改善方面优于对照组，差异有统计学意义（ P ＜0．05），而睡眠障碍评分无显著差异（ P ＞0．05）。疗程结束后治疗组总有效率为8．7％，高于照组的6．8％（χ2=0．130， P ＜0．05）；治疗组不良反应发生率为5．％，对照组为3．2％，2组比较差异有统计学意义（χ2＝1．72， P ＜0．01）。结论参松养心胶囊辅治失眠症安全而有效。
